{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-061079","form_type":"8-K/A","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.543105+00:00","generated_at":"2026-06-01T21:25:39.500756+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Prelude Therapeutics grants 25,000 stock options to Interim CFO Bryant D. Lim","bullets":["Options to purchase 25,000 shares of common stock at $3.86 per share.","Options vest over 4 years (25% at 1 year, then monthly); 10-year term.","Grant approved by Compensation Committee on May 14, 2024, under 2020 Equity Incentive Plan.","Amendment to prior 8-K reporting Lim's appointment as Interim CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-061079","json":"https://secwatch.observer/filing/0000950170-24-061079.json","markdown":"https://secwatch.observer/filing/0000950170-24-061079.md","text":"https://secwatch.observer/filing/0000950170-24-061079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024061079/0000950170-24-061079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024061079/prld-20240408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:25:39.500756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}